X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
EIKANCE (atropine sulfate monohydrate eye drops) are available on prescription for children aged 4 to 14 years, as a treatment to slow the progression of myopia and may be initiated in children when myopia progresses by 1 or more diopters per year.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: Eikance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
FDA approved ANDA products, Atropine Sulfate (anti-muscurainic) Injection (0.1 mg/mL) and 10% Calcium Chloride Injection (100 mg/mL) as a single-dose prefilled syringe, for severe or life-threatening muscarinic effects and for treating hypocalcemia respectively.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atropine Sulfate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: OT-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2023
Details:
The funding will support the continued development of a promising medical countermeasure for nerve agents that contain a stable, fixed-dose combination formulation of atropine and scopolamine.
Lead Product(s): Atropine Sulfate,Scopolamine
Therapeutic Area: Pharmacology/Toxicology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Defense Department
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding December 06, 2022
Details:
Atropine Sulfate Injection inhibits the muscarinic actions of acetylcholine, which is indicated for temporary blockade of severe or life-threatening muscarinic effects and to treat bradyasystolic cardiac arrest.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atropine Sulfate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2022
Details:
Myatro (atropine eye drop)
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
The Phase I SBIR award will fund the formulation and analytical development of a concentrated Atropine Sulfate Drug Product with the aim to aid the military in treating organophosphate poisoning in service members.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Pharmacology/Toxicology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Defense Department
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding April 06, 2022
Details:
OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for anti-allergy and dry eye syndrome and Myopia, Progressive.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: OT-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2021
Details:
SYD-101 is designed to be a best-in-class product with maximum efficacy, comfort and 3-year stability at room temperature, all important product attributes when developing drugs for use in children.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: SYD-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Visionary Ventures
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 10, 2021
Details:
The agreement aims for SYD-101, Sydnexis’ investigational proprietary low dose atropine sulfate formulation, for Europe, Middle East and Africa (EMEA), is currently undergoing a phase III clinical trial, the STAAR study, in Europe and the US to help control myopia progression.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: SYD-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Santen Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 10, 2021
Details:
OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: OT-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2021
Details:
OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: OT-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2021
Details:
OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: OT-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: OT-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2021
Details:
OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: OT-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ora, Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Details:
OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: OT-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ora, Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2021
Details:
OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: OT-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ora, Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
U.S FDA has approved the Company’s Abbreviated New Drug Application (“ANDA”) for Atropine Sulfate injection 0.1mg/mL in the 10 mL Luer-Jet® Prefilled Syringe System.
Lead Product(s): Atropine Sulfate
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
